The Potential of ALLO-715 in Relapsed/Refractory Multiple Myeloma: Doris Hansen, MD

Video

The hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.

This content originally appeared on our sister site, OncLive.

ALLO-715 is an allogeneic, off-the-shelf, novel CAR T-cell therapy directed toward BCMA. The approach offers advantages over autologous CAR T-cell therapies such as mitigating manufacturing challenges encountered with the autologous approach.

Hansen discussed how many patients with relapsed/refractory multiple myeloma experience disease progression during the period required for autologous CAR T-cell therapy generation. This is an area that allogeneic products are also advantageous as patients can receive their ALLO-715 infusion within a period of 5 days.

Initial findings from the ongoing phase 1 UNIVERSAL trial (NCT04093596) demonstrated an overall response rate of 60% with a 320 x 106 dose of CAR cells in 6 patients with relapsed/refractory multiple myeloma. Four patients treated at this dose level achieved at least a very good partial response and minimal residual disease negativity.

On April 21, 2021, the FDA granted ALLO-715 a Regenerative Medicine Advanced Therapy designation as a potential treatment for patients with relapsed/refractory multiple myeloma.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.